Cytokinetics to Present at the Morgan Stanley Global Healthcare Conference
September 05 2018 - 4:00PM
Cytokinetics, Inc. (Nasdaq: CYTK) today announced that Robert I.
Blum, President and Chief Executive Officer, is scheduled to
present a corporate update at the 16th Annual Morgan Stanley Global
Healthcare Conference on Wednesday, September 12, 2018 at 11:40 AM
ET at the Grant Hyatt in New York City.
Interested parties may access the live webcast
of this presentation by visiting the Investors & Media section
of the Cytokinetics website at www.cytokinetics.com. The webcast
replay of the presentation will be archived on the Presentations
page within the Investors & Media section of Cytokinetics’
website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators as potential treatments for
debilitating diseases in which muscle performance is compromised
and/or declining. As a leader in muscle biology and the mechanics
of muscle performance, the company is developing small molecule
drug candidates specifically engineered to increase muscle function
and contractility. Cytokinetics is collaborating with Amgen Inc.
(“Amgen”) to develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of GALACTIC-HF, an
international Phase 3 clinical trial in patients with heart
failure. Amgen holds an exclusive worldwide license to develop and
commercialize omecamtiv mecarbil with a sublicense held by Servier
for commercialization in Europe and certain other countries.
Cytokinetics is collaborating with Astellas Pharma Inc.
(“Astellas”) to develop reldesemtiv (CK-2127107), a next-generation
fast skeletal muscle troponin activator (FSTA). Reldesemtiv has
been granted orphan drug designation by the FDA for the potential
treatment of spinal muscular atrophy. Reldesemtiv was the subject
of a positive Phase 2 clinical study in patients with spinal
muscular atrophy which showed increases in measures of endurance
and stamina consistent with the mechanism of action. Reldesemtiv is
currently the subject of two ongoing Phase 2 clinical trials in
patients with chronic obstructive pulmonary disease and amyotrophic
lateral sclerosis. Astellas is also conducting a Phase 1b clinical
trial of reldesemtiv in elderly adults with limited mobility.
Astellas holds an exclusive worldwide license to develop and
commercialize reldesemtiv. Licenses held by Amgen and Astellas are
subject to Cytokinetics' specified co-development and
co-commercialization rights. Cytokinetics continues its 20-year
history of innovation with three new muscle biology directed
compounds advancing from research to development in 2018. For
additional information about Cytokinetics, visit
www.cytokinetics.com.
Contact:
Cytokinetics
Diane
Weiser
Vice President, Corporate Communications, Investor Relations(650)
624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024